8-K: 23andMe Reports Significant Revenue Decline and Increased Losses in Fiscal Year 2024

23andMe's fiscal year 2024 results show a substantial decrease in revenue and a significant increase in net losses, primarily due to the end of a key collaboration and lower sales.

Summary

• 23andMe reported its financial results for the fourth quarter and full fiscal year 2024, which ended March 31, 2024.
• Total revenue for the fourth quarter was $64 million, a 31% decrease compared to $92.4 million in the same period last year.
• The decrease in revenue was primarily due to lower research revenue following the conclusion of the GSK collaboration in July 2023, and lower sales of PGS kits and telehealth orders.
• Full year revenue for 2024 was $219.6 million, a 27% decrease compared to $299.5 million in 2023.
• Operating expenses for the fourth quarter increased to $239 million, compared to $109 million in the same period last year, primarily due to a $153 million non-cash goodwill impairment charge.
• The full year operating expenses were $781 million, compared to $459 million in the prior year, including $352 million in non-cash goodwill impairment charges.
• Net loss for the fourth quarter was $209 million, compared to a net loss of $64 million in the same period last year.
• The full year net loss was $667 million, compared to a net loss of $312 million in the prior year.
• Adjusted EBITDA for the fourth quarter was a loss of $33 million, compared to a loss of $39 million in the same period last year.
• Adjusted EBITDA for the full year was a loss of $176 million, compared to a loss of $161 million in the prior year.
• The company ended the fiscal year with $216 million in cash and cash equivalents, down from $387 million the previous year.
• 23andMe has formed a Special Committee to review strategic alternatives to maximize shareholder value.
• The CEO is considering a proposal to acquire all outstanding shares she does not currently own.
• The company received an extension from Nasdaq to regain compliance with the minimum bid price requirement until November 4, 2024.

Sentiment

Score: 3

Explanation: The document indicates a significant downturn in financial performance, with substantial revenue declines, increased losses, and a decrease in cash reserves. The strategic review and potential acquisition by the CEO add uncertainty. While there are some positive developments in research and product launches, the overall sentiment is negative due to the financial challenges.

Positives

• 23andMe launched a new ancestry feature called Historical Matches.
• Three new genetic reports for breast, colorectal, and prostate cancer were announced for 23andMe+ members.
• The first patient was dosed in a Phase 1 clinical trial for a new cancer therapy, 23ME-01473.
• The company completed enrollment of the 23ME-00610 phase 1/2a clinical trial in April 2024.
• The company will be presenting posters at ASCO on the neuroendocrine and ovarian cohorts for 23ME-00610 in June 2024.
• The company saw growth in membership services revenue which partially offset the revenue decline.

Negatives

• There was a significant decrease in research revenue due to the conclusion of the GSK collaboration.
• Consumer services revenue declined due to lower PGS kit sales and telehealth orders.
• Operating expenses increased substantially due to non-cash goodwill impairment charges.
• The company experienced a significant increase in net losses for both the quarter and the full year.
• The company's cash reserves have decreased significantly year over year.
• The company is not providing financial guidance for FY2025 due to the strategic review.

Risks

• The company is facing challenges in maintaining revenue growth after the conclusion of the GSK collaboration.
• The decrease in consumer services revenue indicates a potential weakness in the core business.
• The significant increase in operating expenses and net losses raises concerns about the company's financial stability.
• The company's cash reserves are declining, which could impact its ability to fund future operations.
• The ongoing strategic review and potential acquisition by the CEO create uncertainty about the company's future direction.
• The company needs to regain compliance with Nasdaq's minimum bid price requirement by November 4, 2024, or face delisting.

Future Outlook

The company is not providing financial guidance for FY2025 due to the ongoing strategic review. They are looking forward to a transformative FY2025.

Management Comments

• The company had a productive fourth quarter and solid end to the year, continuing to add value for members of 23andMe+ and advancing our clinical stage assets, said Anne Wojcicki, Co-Founder & CEO of 23andMe.
• We continue to work to build value for customers and shareholders and are looking forward to a transformative FY2025.

Industry Context

The decline in revenue and increased losses highlight the challenges faced by companies in the consumer genetics and biopharmaceutical sectors, particularly after the conclusion of major collaborations. The strategic review and potential acquisition suggest a period of significant change for the company, which is not uncommon in this competitive industry.

Comparison to Industry Standards

• The 31% decrease in quarterly revenue and 27% decrease in annual revenue is significantly worse than many of its peers in the biotech and consumer genetics space. For example, companies like Myriad Genetics (MYGN) and Invitae (NVTA) have reported more stable revenue figures, although they also face challenges.
• The large goodwill impairment charges of $153 million in Q4 and $352 million for the full year indicate that 23andMe overpaid for the acquisition of Lemonaid Health Limited, which is a common issue in the industry when companies try to expand rapidly.
• The adjusted EBITDA loss of $176 million for the year is also concerning, as many biotech companies aim to achieve profitability or at least reduce losses as they mature. Companies like Exact Sciences (EXAS) and Guardant Health (GH) have shown better control over their losses, although they are also in different stages of development.
• The decrease in cash reserves from $387 million to $216 million is a significant concern, as it limits the company's ability to fund research and development and other operational activities. Many biotech companies maintain a strong cash position to support their long-term growth plans.
• The need for a strategic review and the potential acquisition by the CEO suggest that the company is facing significant challenges in its current business model. This is not uncommon in the biotech industry, where companies often need to pivot or restructure to survive.

Stakeholder Impact

• Shareholders are negatively impacted by the significant decrease in revenue, increased losses, and declining cash reserves.
• Employees may be concerned about the company's financial stability and potential restructuring.
• Customers may be affected by changes in the company's product offerings and services.
• Suppliers and creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company will continue to enroll patients in the Phase 1 clinical trial for 23ME-01473 throughout fiscal year 2025.
• The company expects to announce results of the Phase 1 clinical trial for 23ME-01473 later in calendar year 2025.
• The company will present posters at ASCO on the neuroendocrine and ovarian cohorts for 23ME-00610 in June 2024.
• The Special Committee will continue to review strategic alternatives to maximize shareholder value.
• The company needs to regain compliance with Nasdaq's minimum bid price requirement by November 4, 2024.

Key Dates

Keywords

23andMe, genetics, biopharmaceutical, revenue, net loss, EBITDA, clinical trial, cancer, research, strategic review, Nasdaq, goodwill impairment, consumer services, therapeutics